Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate

Roberto Alfonso Accinelli a,b,c,*, Grisel Jesús Ynga-Meléndez d, Juan Alonso León-Abarca a, Lidia Marianella López a, Juan Carlos Madrid-Cisneros d, Juan Diego Mendoza-Saldaña b

a Instituto de Investigaciones de la Altura. Universidad Peruana Cayetano Heredia, Lima, Peru
b Facultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia, Lima, Peru
c Hospital Cayetano Heredia, Peru
d Centro Materno-Infantil Tahuantinsuyo Bajo, Lima, Peru

ARTICLE INFO

Keywords:
Hydroxychloroquine
Azithromycin
SARS-CoV-2
COVID-19
Mortality
Time-to-Treatment

ABSTRACT

Background: Currently, there is no formally accepted pharmacological treatment for COVID-19.

Materials and methods: We included COVID-19 outpatients of a Peruvian primary care center from Lima, Peru, who were treated between April 30 - September 30, 2020, with hydroxychloroquine and azithromycin. Logistic regression was applied to determine factors associated with case-fatality rate.

Results: A total of 1265 COVID-19 patients with an average age of 44.5 years were studied. Women represented 50.1% of patients, with an overall 5.9 symptom days, SpO2 97%, temperature of 37.3 °C, 41% with at least one comorbidity and 96.1% one symptom or sign. No patient treated within the first 72 h of illness died. The factors associated with higher case fatality rate were age (OR = 1.06; 95% CI 1.01–1.11, p = 0.021), SpO2 (OR = 0.87; 95% CI 0.79–0.96, p = 0.005) and treatment onset (OR = 1.16; 95% CI 1.06–1.27, p = 0.002), being the latter the only associated in the multivariate analysis (OR = 1.18; 95% CI 1.05–1.32, p = 0.005). 0.6% of our patients died.

Conclusions: The case fatality rate in COVID-19 outpatients treated with hydroxychloroquine/azithromycin was associated with the number of days of illness on which treatment was started.

1. Introduction

The rapid spread of the virus referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a devastating worldwide pandemic. Despite the astonishingly rapid development of effective vaccines, most countries continue to suffer from the tragic consequences of the coronavirus disease 2019 (COVID-19). There is still a need for drugs that effectively control the disease. Unfortunately, COVID-19 has proven elusive and non-responsive to most treatment options as indicated by several clinical trials that failed to demonstrate significant reduction in morbidity and mortality of COVID-19 patients [1,2]. Perhaps most disheartening is the fact that drugs proven to possess strong anti-infectious and anti-inflammatory properties and that have been successfully employed in other viral diseases failed to show statistical improvement in several clinical trials in COVID-19 patients. Two concrete examples are Chloroquine (CQ) and its metabolite Hydroxychloroquine (HCQ). Successfully used to prevent and treat malaria and amebiasis for many years [3], these drugs yielded conflicting results in various clinical trials [4]. Furthermore, its usage or treatment interruption could be confounded by the known side effects of CQ and HCQ which include mild gastrointestinal and more serious cardiovascular and neurological effects. This is a particularly important consideration when treating patients at risk of developing severe forms of COVID-19 [4,5].

However, notwithstanding the known limitations and well-justified reservation for the use of these drugs, there is one aspect that requires further investigation: the fact that in viral infections such as influenza,
there is a relationship between early antiviral therapy and survival. It is the rapid elimination of pathogens and the early reduction in the viral load that seems to be decisive to avoid irreversible injury due to progression of the disease [6]. This is particularly relevant for the use of CQ and HCQ in the context of COVID-19 [7], and much can be learned from countries that have considerable clinical experience with the use of these drugs in the treatment of malaria and other infectious diseases. Indeed, the healing properties of the bark of the tree Cinchona officinalis, the source of the natural quinine, was first discovered by the Incas, and clinically applied to cure malaria as early as the 1600’s, making the Cinchona tree the national tree of Peru.

Thus, when the first case of COVID-19 was diagnosed in Peru on March 6th, 2020, clinicians experienced with the use of HCQ in the treatment of other diseases employed this drug to combat COVID-19. They based its use on their clinical experience and the knowledge that HCQ significantly decreases viral load in particular when associated with azithromycin (AZIT). To these clinicians, the long-term use of low doses of AZIT was known to reduce exacerbations of poorly controlled asthma, which has been attributed to the suppressive effect of AZIT on the inflammatory TNF pathways [8]. The use of this treatment regimen was further encouraged by early reports that HCQ not only decreased significantly the viral load, but when associated with AZIT, was also able to control the infection in COVID-19 patients [9].

Cloroquine, the derivate of the natural quinine, is a 9-aminoquinolineline that has first been described in 1934, and used to combat various viruses since 1960 [10]. In 1978 it was demonstrated that CQ is an acitdrotic dibasic agent that increases the pH of lysosomes [11], and alters cellular metabolism [12]. This pH effect in lysosomes and other cytoplasmic organelles contributes to the suppression of viral replication. Together with its anti-inflammatory action as a suppressor of TNF alpha and Interleukin 6, this drug seems to be an ideal candidate to treat viruses since 1960 [10]. In 1978 it was demonstrated that CQ is an antiviral drug that has the potential to significantly reduce the viral load in the context of emerging understanding of the pathophysiology of SARS-CoV-2 infection in order to determine the impact of early outpatient treatment on hospitalization and mortality [27]. In this report we present the results in 1265 patients treated on an outpatient basis at the Centro Materno-Infantil (CMI) de Tahuantinsuyo Bajo, a 1-4-level health center in the city of Lima.

2. Material and methods

The present study analyzed anonymized data from the database of COVID-19 patients attended at the CMI Tahuantinsuyo Bajo, a primary care facility in the city of Lima, between April 30 and September 30, 2020.

Patients arrived at a dedicated triage site for patients with suspected COVID-19 infection. There, vital signs were taken, including SpO2, and the attending physicians took the patient history and performed a clinical examination to determine whether they met COVID-19 patient clinical criteria according to the guidelines of the Peruvian Ministry of Health. All patients were registered in the respective epidemiological data file and the information included vital signs, comorbidities, symptoms and treatment onset, consisting of 200 mg HCQ every 8 h for 7–10 days in combination with 500 mg AZIT on the first day, followed by 250 mg for 4 days. Data on days from symptom onset to treatment was collected as well. The patients were followed up with daily telephone controls and if any symptoms of deterioration or side effects appeared, they were summoned to the clinical facility. Follow-up was carried out not only with the patients but also with their contacts, with the aim of providing treatment as soon as the first symptoms appeared. Every day the epidemiology team recorded and shared patient information to the physician coordinating the COVID-19 registry. The information was transcribed into an Excel spreadsheet and the cases were followed up after discharge until they were sure of their condition. If the information could not be obtained by telephone, a home visit was done by the rapid a response team also established under Peruvian COVID-19 guidelines.

The treatment started as soon as the attending physician determined that the patient exhibited symptoms that met the COVID-19 patient clinical criteria according to the guidelines of the Peruvian Ministry of Health. Some of these patients arrived at the hospital with a positive test, but most did not. Those that were not tested before arrival were asked to take the test. This test was not readily available at the center, albeit it continues to be offered at no cost at some government testing sites. Given that during the study period it could take almost a week to process and register the result of the NAAT test, and because tests tend to be less accurate within three days of exposure, the treatment regimen was
started irrespective of any result if a patient met all the clinical criteria for COVID-19. Statistical analysis was performed with the Stata 14 statistical package (Stata Corporation, College Station, Texas, USA). Categorical variables were presented as frequencies and percentages and their respective 95% confidence intervals (95%CI), continuous variables as means or medians along standard deviations (SD) or interquartile ranges (IQR). To determine the risk factors associated with death, a logistic regression analysis was performed, odds ratios were presented with their respective 95%CI and a p value of less than 0.05 was considered statistically significant.

This study was approved by the Institutional Human Ethics Committee of the Universidad Peruana Cayetano Heredia (approval code: 203939). This study did not require individual consent from the participants because it analyzed de-identified data from an already existing database. Cayetano Heredia University’s researchers analyzed the information that was previously registered and systematized by the team of physicians in charge of primary care at the health center.

3. Results

A total of 1265 clinically diagnosed COVID-19 patients were studied with an average age of 44.5 years, 50.1% being women, with a time of symptom onset to treatment of 5.9 days, SpO2 of 97%, temperature of 37.3 ◦C, with 41% with at least one comorbidity and 96.1% with at least one symptom or sign (Table 1). The most common comorbidities were obesity (17.3%), hypertension (8.3%), chronic respiratory disease (7.2%) and diabetes (6.1%) (Table 2). The most common symptoms were cough (85.1%), malaise (81.7%), sore throat (76.7%), sensation of thermal rise (54.2%) and dyspnea (33.8%) (Table 3).

At follow-up, there were 7 deaths in total, all men with a mean age of 57.7 years, SatO2 96%. Four of the deceased patients carried one known comorbidity (hypertension, obesity, diabetes and chronic respiratory disease), three had no comorbidity. The one aged 29 years old had obesity and a 98% SpO2 at first encounter, while the patient age 39 years old had no known comorbidities and a 98% SpO2. The most common symptoms were cough (100%), malaise (100%), sore throat (85.7%), dyspnea (71.4%), nasal congestion (42.9%) and febrile sensation (42.9%) (Table 3). Logistic regression showed that those factors associated with higher mortality were age (OR 1.06; 95% CI 1.01–1.11, p = 0.021), SpO2 (OR 0.87; 95% CI 0.79–0.96, p = 0.005) and number of days until the start of treatment (OR 1.16; 95% CI 1.06–1.27, p = 0.002). However, in a multivariate analysis the time of illness elapsed before receiving treatment was the only factor associated with higher mortality (OR 1.18; 95%CI 1.05–1.32, p = 0.005) (Table 4).

The case-fatality rate of this cohort of patients treated with HCQ-AZIT was 0.6%. No female patient died and the mortality among males was 1.32% (Table 5). Remarkably, none of those treated in the first 72 h of illness onset died. Deaths occurred on days four, when two died, and on days six, seven, eight, twelve and thirty-one after onset. All but nine patients

| Table 1 | Characteristics of COVID-19 patients treated with hydroxychloroquine and azithromycin at CMI Tahuantinsuyo Bajo. |
|---|---|
| Variables | All patients (n = 1265) | Dead (n = 7) |
| Age (years) | 1265 | 44.5 ± 14.8 | 57.7 ± 20.6 |
| SpO2 (%) | 1057 | 97 ± 2 | 96 ± 4 |
| Temperature ( ◦C) | 1108 | 37.3 ± 0.8 | 37.4 ± 0.7 |
| Time from symptom onset to treatment (days) | 1202 | 5.9 ± 4 | 10.3 ± 9.5 |
| Symptoms (number)* | 1265 | 5 ± 3 | 6 ± 4 |
| Comorbidities (number)* | 1265 | 0 ± 1 | 1 ± 1 |
| Height (meters) | 420 | 1.62 ± 0.09 | 1.64 ± 0.1 |
| Weight (kg) | 418 | 72.9 ± 13 | 73 ± 25.7 |
| BMI (kg/m2) | 418 | 27.8 ± 4.2 | 26.8 ± 7.5 |
| Characteristics | n % | CI 95% n % |
| 0–20 years | 39/1265 | 3.1 ± 2.3–4.2 | 0 ± 0 |
| 20–40 years | 439/1265 | 34.7 ± 32.1–37.4 | 2 ± 28.6 |
| 40–60 years | 590/1265 | 46.6 ± 43.9–49.4 | 2 ± 28.6 |
| 60–80 years | 177/1265 | 14 ± 12.2–16.0 | 1 ± 14.3 |
| 80–100 years | 20/1265 | 1.6 ± 1.0–2.4 | 2 ± 28.6 |
| Sex (female) | 634/1265 | 50.1 ± 47.4–52.9 | 0 ± 0 |
| At least one comorbidity | 470/1265 | 37.2 ± 34.5–39.9 | 4 ± 57.1 |
| SpO2 <92% | 32/1265 | 2.5 ± 1.8–3.6 | 1 ± 14.3 |
| Tested for SARS-CoV-2 (any test) | 134/1265 | 10.6 ± 9.2–12.7 | 5 ± 3.6 |
| Treatment discontinuation | 10/1265 | 0.8 ± 0.4–1.5 | 1 ± 10% |

| Table 2 | Comorbidities in COVID-19 patients who were treated with hydroxychloroquine and azithromycin. |
|---|---|
| Comorbidities | All patients (n = 1265) | Dead (n = 7) |
| obesity | 219 | 17.3 ± 15.3 | 19.5 ± 14.3 |
| Hypertension | 105 | 8.3 ± 6.9 | 10 ± 14.3 |
| Respiratory disease | 91 | 7.2 ± 5.9 | 8.8 ± 14.3 |
| Diabetes | 77 | 6.1 ± 4.9 | 7.5 ± 14.3 |
| Endocrinological disease | 18 | 1.4 ± 0.9 | 2.2 ± 0 |
| Cardiovascular disease | 13 | 1 ± 0.6 | 1.8 ± 0 |
| Gastrointestinal disease | 12 | 0.9 ± 0.5 | 1.7 ± 0 |
| Neurological disease | 10 | 0.8 ± 0.4 | 1.3 ± 0 |
| Rheumatologic disease | 7 | 0.6 ± 0.3 | 1.2 ± 0 |
| Immunosuppression | 7 | 0.6 ± 0.3 | 1.2 ± 0 |
| Pregnant women | 6 | 0.5 ± 0.2 | 1.1 ± 0 |
| Psychiatric disease | 5 | 0.4 ± 0.2 | 0.9 ± 0 |
| Surgical pathology | 4 | 0.3 ± 0.1 | 0.8 ± 0 |
| Hematologic disease | 3 | 0.2 ± 0.1 | 0.7 ± 0 |
| Renal disease | 2 | 0.2 ± 0 | 0.6 ± 0 |
| Neoplastic disease | 2 | 0.2 ± 0 | 0.6 ± 0 |

| Table 3 | Symptoms presented by COVID-19 patients who were treated with hydroxychloroquine and azithromycin. |
|---|---|
| Symptoms | All patients (HCQ + AZIT) (n = 1265) | Dead (n = 7) |
| Cough | 1076 | 85.1 ± 83 | 86.9 ± 7 |
| General discomfort | 1034 | 81.7 ± 79.5 | 83.8 ± 7 |
| Sore throat | 970 | 76.7 ± 74.3 | 78.9 ± 6 |
| Fever | 685 | 54.2 ± 51.4 | 56.9 ± 3 |
| Dyspnea | 427 | 33.8 ± 31.2 | 36.4 ± 5 |
| Nasal congestion | 397 | 31.4 ± 28.9 | 34 ± 3 |
| Headache | 360 | 28.5 ± 26 | 31 ± 2 |
| Chills | 259 | 20.5 ± 18.3 | 22.8 ± 0 |
| Muscle pain | 207 | 16.4 ± 14.4 | 18.5 ± 2 |
| Joint pain | 223 | 17.6 ± 15.6 | 19.8 ± 1 |
| Chest pain | 141 | 11.2 ± 9.5 | 13 ± 1 |
| Diarrhea | 103 | 8.1 ± 6.8 | 9.8 ± 1 |
| Nausea | 82 | 6.3 ± 5.2 | 8 ± 0 |
| Anemia | 65 | 5.3 ± 4.5 | 6.5 ± 1 |
| Ageusia | 49 | 3.9 ± 2.9 | 5.1 ± 1 |
| Vomiting | 39 | 3.1 ± 2.3 | 4.2 ± 0 |
| Back pain | 26 | 2.1 ± 1.4 | 3 ± 0 |
| Unspecified pain | 21 | 1.7 ± 1.1 | 2.5 ± 1 |
| Abdominal pain | 11 | 0.9 ± 0.5 | 1.6 ± 0 |
| Irritability | 8 | 0.6 ± 0.3 | 1.3 ± 0 |
| Eye redness | 4 | 0.3 ± 0.1 | 0.8 ± 0 |
| Decreased appetite | 3 | 0.2 ± 0.1 | 0.7 ± 0 |
| Dizziness | 1 | 0 ± 0 | 0 ± 0 |
| Skin rash | 1 | 0 ± 0 | 0 ± 0 |
4. Discussion

Of the 1265 COVID-19 patients treated at Tahuantinsuyo Bajo with HCQ/AZT, 0.6% died (Table 1). This outcome is consistent with the first European study that used the same treatment regimen for 1061 patients. The case-fatality rate in this healthcare center was 0.75% [28]. The mortality rate among the 1265 patients treated with this specific regimen was six times lower than the national average [29]. As of September 1st, 2020, the updated case counts show that 74687 out of 694314 COVID-19 Peruvian patients died (case-fatality rate of 10.8%), being 13.2% (49121/372685) for men and 7.9% (25566/321629) for women [30]. Unfortunately, as of August 25th, Peru has one of the highest CFR of COVID-19 related deaths and ranks on seventh position with 6086 deaths per million inhabitants.

![Days since symptom onset](image-url)
among 100 nursing home residents there was less mortality among those \(<0.001\) compared to the 58 hospitalized patients out of 377 (15.4\%) on day onset, 41\% at the first day of symptoms, matched for age, sex and BMI in those who received HCQ-AZIT on the first day of symptom onset (OR \(0.16, 95\%\ CI 0.06\)–0.39). The rate of ICU admissions and mortality rate were also lower in the HCQ-AZIT group compared to the SC (0.77 vs. 1.5 \(p=0.045\)) and 47 (4\%) patients with no outpatient exposure died compared to 2 (2\%) patients with outpatient exposure to HCQ [43]. In a group of Brazilian COVID-19 patients with an average delay from the start of symptoms to ER visit of 4.6 days the use of HCQ had a significant protective effect of 55\% (OR 95\% 0.45 (0.25–0.80), \(p=0.0065\)) for hospitalizations [44].

In Saudi Arabia there were 5541 study participants, almost 33\% \((n=1817)\) received HCQ in addition to SC while 67.2\% \((n=3724)\) received the SC only, with significant fewer hospital admissions in the HCQ group compared to the SC (171 (9.36\%) vs. 617 (16.6\%), \(p<0.001\)). This corresponded to a relative risk reduction in hospital admission of 43\%.

So, all the studies with HCQ since the first week of symptoms in COVID-19 patients, including this, demonstrate protection for hospitalization and/or CFR. And with other drugs also used in COVID-19 for second indication, because their action over SARS-CoV-2 with excellent selectivity index, as ivermectin [46], colchicine [47], fluvoxamine [48], they have nice results when patients received them since the first symptoms days.

### 4.2. Sex

Although 50.1\% of our patients were female, none of them died (Table 5). The sexual dimorphism in the evolution of COVID-19 may be hormonally based. Women produce higher levels of estrogens which is known to cause a more potent innate, cellular and humoral response, which is associated with a greater number of regulatory T cells and immunoglobulins [49]. Progestosterone has higher levels in women and it is a Sigma R1/R2 active drug with anti viral action to SARS-CoV-2 [25]. Moreover, the immune cells of females exhibit a 10-fold higher expression of TLR [50]. Another factor could be the presence of two X chromosomes which confers a stronger innate and adaptive immune response to viral infections in women [51]. By contrast, males could have a higher susceptibility to SARS-CoV-2 as they express more RCT2 [52], which activity increases after ovariectomy and is reduced after orchietomy [53], human bronchial epithelial cells treated with 17β-estradiol express lower levels of RCT2 mRNA [54], and the serine protease gene TMPRSS2, required for virus entry [55], increases after exposure to androgens [56].

### 4.3. Age

With HCQ/AZIT treatment, mortality in male patients did not exceed

---

**Fig. 2.** Deaths by days from symptom onset to treatment \((p=0.0039)\).
was primarily based on clinical guidelines [25]. In China, suspected older than 80 years (Table 5). Multiple factors contribute to the inflammatory response associated with cytokine storm in patients with severe COVID-19 resulting in an increased mortality among the elderly [57].

4.4. Comorbidities

The four most prevalent comorbidities of COVID-19 are hypertension, diabetes, cardiovascular and respiratory diseases, all of which are closely associated with obesity which is a major factor in the severity of morbidity and mortality of COVID-19 [58]. In the present cohort, 17.3% were obese (Table 2). This may affect ACE2 receptor expression in adipocytes and virus entry [59]. Moreover, in diabetic patients there is chronic inflammation, and in the elderly, inflammatory senescence aggravates the evolution of the disease, increasing the vulnerability in patients that do not control their glycemia, which may in part explain why diabetes is the comorbidity with the highest case fatality number [60]. Although the presence of comorbidities confers a much higher mortality risk in COVID-19 [61], their presence in our patients treated with HCQ/AZT was not associated with the case-fatality rate (Table 4).

A limitation of the present investigation is the underreporting of information, mainly of comorbidities and symptoms. In order to prevent an increased mortality among healthcare workers, forty percent of healthcare workers in Peru were sent home from the beginning of the pandemic, either because they were elderly with/without risk factors or because they had medical comorbidities. In addition, many of the healthcare workers that continued became ill in the meantime, which could have affected the completeness of the information.

Another limitation of the present investigation is that the diagnosis was primarily based on clinical guidelines [25]. In China, suspected COVID-19 cases are considered on the basis of epidemiological and clinical manifestations [62]. In Perú, the definition of a “suspected COVID-19 case” encompass a group of symptoms classically associated with COVID-19 according to national guidelines, while the definition of a “probable case” includes additional epidemiological or imaging criteria. Specific tests to detect the presence of the SARS-CoV-2 antigens or RT-PCR assays are only for diagnostic confirmation [63]. Of note, most healthcare centers faced difficulties securing enough tests for their assigned population. Of the 1265 patients evaluated in this study, only 134 (10.6%) had a test performed that was positive in 38 cases (28.4%), and both groups shared similar characteristics.

This limitation is typical for many countries including Peru, because the pandemic quickly overwhelmed the local health care systems. Global COVID-19 studies show that the median time from the first symptom onset to hospital admission is 7 days, 5–8 days for dyspnea, 8–9 days for acute respiratory distress syndrome, 10 to 5 days for mechanical ventilation and admission to hospital, and 5 days for mechanical ventilation and admission to the intensive care unit [64]. Any delays in the initiation of treatment would increase the frequency of hospitalization and worsen the outcomes in a healthcare system that experiences severe shortages in all aspects of clinical care. Moreover, during the first week of illness the positivity of RT-PCR is not more than 71% [65] and that of the combined IgM/IgG test is even lower at 39.3% [66]. Thus, relying on the positivity of any one of these tests in order to make the diagnosis of COVID-19 is inadequate because the diagnosis is delayed or never made. Thus, the Peruvian government decided to address this limitation by regulating that the diagnosis should be done on a clinical suspicion basis and the tests were only to confirm the patient as a COVID-19 case [26]. Indeed, as shown in the present study the reliance on the clinical diagnosis was an important prerequisite to ensure not only the early treatment onset but also an increased therapeutic success.

The case-fatality rate with this treatment regimen was 0.6%, which was significantly lower than the national average. There is a large discrepancy between the case-fatality rate reported in this study and the rest of the country. Peruvian government put in its guidelines HCQ/AZT as one of the treatments for these patients [67]. At the same time, the World Health Organization stated no recommendation in favor of any specific treatment at inpatient settings to date, along Peruvian medical societies [68], physicians [69] and mass media [70]. This could have led to the underusage of the national COVID-19 guidelines which suggested diverse early treatment schemes. On another hand, the primary-care physicians at the Tahuantinsuyo Bajo Maternal and Child Center continued to treat patients with COVID-19 with HCQ-AZT, being the first primary care center in Lima that treated them early including patients outside its area of influence. This situation could explain the difference in the results between Tahuantinsuyo Bajo and the rest of the Peruvian territory.

In conclusion, our study showed that case-fatality rate in COVID-19 patients treated on an outpatient basis with HCQ/AZT was associated with the number of days of illness when treatment was initiated.

CRediT authorship contribution statement

Roberto Alfonso Accinelli: Conceptualization, Resources, Data curation, Writing – original draft, Writing – review & editing, Supervision, Project administration, Funding acquisition. Grisel Jesús Yanga-Meléndez: Investigation, Resources, Data curation, Writing – original draft, Funding acquisition. Juan Alonso León-Abarca: Methodology, Software, Validation, Formal analysis, Investigation, Writing – original draft, Writing – review & editing, Visualization. Lidia Marianna Lopez: Methodology, Software, Validation, Formal analysis, Investigation, Writing – original draft, Writing – review & editing, Visualization. Juan Carlos Madrid-Cisneros: Investigation, Writing – original draft, Visualization. Juan Diego Mendoza-Saldana: Investigation, Writing – original draft, Visualization.

Acknowledgments

The authors gratefully acknowledge the constructive suggestions given by Professor Nino Ramirez (Director, Center for Integrative Brain Research, Seattle Children’s Research Institute) on the final version of the present manuscript. We’d also like to acknowledge the members of the multidisciplinary team of the Centro Materno Infantil Tahuantinsuyo Bajo Lic. Rosa Chinchay Matta, Dr. Jose Luis Pando Hermosilla, Dr. Jose Roberto Espinoza Acosta, Dr. Veronica Cecilia Campos Aparcana, Dr. Cesar Vidal Osco Tamayo, and Dr. Cesar Vidal Osco Tamayo. Cesar Vidal Osco Tamayo, Dr. Henry Fabio Carrion Flores, Dr. Jean Huerta Jara, Lic. Victoria Sallo Accostuma, Lic. Ines Matta Bejarano, Lic. Maribel Reano Rodriguez, Lic. Marisa Rios Jara, Tec. Jackie Yvonne Greenwich Centeno, Tec. Irene Alejo Mendoza De Quispe, Tec. Hayde Manuico Mallma, Tec. Liliana Janeth Hernandez Minope and the students of the Faculty of Medicine of the Universidad Peruana Cayetano Heredia who confirmed the final condition of each patient Seungseo Choi, Niels Víctor Rea–Vidal Osco Tamayo, and Dr. Henry Fabio Carrion Flores, Dr. Jean Huerta Jara, Lic. Victoria Sallo Accostuma, Lic. Ines Matta Bejarano, Lic. Maribel Reano Rodriguez, Lic. Marisa Rios Jara, Tec. Jackie Yvonne Greenwich Centeno, Tec. Irene Alejo Mendoza De Quispe, Tec. Hayde Manuico Mallma, Tec. Liliana Janeth Hernandez Minope and the students of the Faculty of Medicine of the Universidad Peruana Cayetano Heredia who confirmed the final condition of each patient Seungseo Choi, Niels Víctor Rea–

References

[1] Apaydin CB, Guran G, Cihan-Ustündag G. Small-molecule antiviral agents in ongoing clinical trials for COVID-19. Curr Drug Targets 2021 Feb 14. https://doi.org/10.2174/1389450122666202101211250. In press.
[2] Ebina-Shibuya R, Namkoong H, Hooria N, Kato H, Hara Y, Kobayashi N, Kaneko T. Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials. J Thorac Dis 2021 Jan;13(1):202–12.
[3] Pasteck KA, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, Pullen MF, Rajasingham R, McDonald EG, Lee TC, Schwartz JS. Review: hydroxychloroquine
and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis 2020 Apr 1;7(4).

[26] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[27] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[28] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[29] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[30] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[31] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[32] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[33] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[34] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[35] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[36] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[37] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[38] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[39] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[40] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[41] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[42] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[43] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.

[44] McGough PA, Kelleher RJ, Driscoll L, Lesina R, Tumlin J, Wheaton RK, Katz N, Lepor NE, Pajar ja, Kehar Singh. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021 Jan 13;134(1):11–22.
[54] Stelzig KE, Canepa-Escaro F, Schiliro M, Berdnikovs S, Prakash YS, Chiarella SE. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2020 Jun;318(6):L1280–1.

[55] Gkogkou E, Barnasas G, Vougas K, Trougakos IP. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators. Redox Biol 2020 Sep 1;36:101615.

[56] Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L, Nelson PS. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999 Sep 1;59(17):4186–4.

[57] Meftahi GH, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging”. Inflamm Res 2020 Sep;69(9):825–39.

[58] Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020 May 1;94:91–5.

[59] Ritter A, Kreis N-N, Louwen F, Yuan J. Obesity and COVID-19: molecular mechanisms linking both pandemics. Int J Mol Sci 2020 Aug;21(16).

[60] Nandy K, Salunke A, Pathak SK, Pandey A, Doctor C, Puj K, et al. Coronavirus disease (COVID-19): a systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. Diabetes Metab Syndr 2020;14(5):1017–25.

[61] Callender LA, Curran M, Bates SM, Mairese M, Weigand J, Betts CJ. The impact of pre-existing comorbidities and therapeutic interventions on COVID-19. Front Immunol 2020;11:1991.

[62] China National Health Commission. Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment. seventh ed. China National Health Commission; 2020 Mar Available from: http://hfjy.meetingchina.org/ntsx/news/show/cn/3397.html.

[63] de Salud del Perú Ministerio. Directiva Sanitaria N° 135-MINSA/CDC-2021. Directiva sanitaria para la vigilancia epidemiológica de la enfermedad por coronavirus (COVID-19) en el Perú. Ministerio de Salud del Perú. 2020 July. Available from, https://cdn.www.gob.pe/uploads/document/file/2024343/Directiva%20Sanitaria%20N%20135-MINSA%CDC-2021.pdf.

[64] Xie Y, Wang Z, Liao H, Marley G, Wu D, Tang W. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis 2020 Aug;20(1):640.

[65] Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W. Sensitivity of chest CT for COVID-19: Comparison to RT-PCR. Radiology 2020 Aug;296(2):E115–7.

[66] Guo C-C, Mu J-Q, Nie H. Seropositivity rate and diagnostic accuracy of serological tests in 2019-nCoV cases: a pooled analysis of individual studies. Eur Rev Med Pharmacol Sci 2020 Oct;24(19):10208–18.

[67] de Salud del Perú Ministerio. Prevención, Diagnóstico y Tratamiento de personas afectadas por COVID-19 en el Perú. Resolución Ministerial N° 270-2020-MINSA. Ministerio de Salud del Perú. 2020 May. Available from, https://www.gob.pe/insti tucion/minsa/normas-legales/563764-270-2020-minsa.

[68] Sociedad Peruana de Medicina Interna. COMUNICADO CONJUNTO SPMI, SPN, SOPEMI, SOPEHE, SOPEIT SOBRE USO DE MEDICAMENTOS PARA EL COVID-19 A LA OPINIÓN PÚBLICA. 2020 Jun. Available from: http://www.medicina interna.net.pe/?q=node/493.

[69] Chirinos JA, Corrales-Medina VF, Heresi-Davila G, Hernandez AV, Málaga G, Mallea JM, Miranda JJ, Morey OO, Rodríguez-Mori JE, Salinas-Gamero JE, Serpa-Alvarez J. Sobre las recomendaciones del Ministerio de Salud para el tratamiento farmacológico de la COVID-19 en el Perú. Acta Méd Perú 2020 Apr;37(2):231–5.

[70] Huerta E. El manejo ambulatorio del COVID-19. Diario El Comercio. 2020 Oct. Available from: https://elcomercio.pe/tecnologia/ciencias/elmer-huerta-coronavirus-salud-hidroxicloroquina-ivermectina-el-manejo-ambulatorio-del-covid-19-noticia.